A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib.

Trial Profile

A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2015

At a glance

  • Drugs Dasatinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms CMR-CML
  • Most Recent Events

    • 14 Jun 2015 Results presented at the 20th Congress of the European Haematology Association.
    • 14 Jun 2015 Status changed from active, no longer recruiting to completed, according to abstract presented at 20th Congress of the European Haematology Association, which stated that patients were enrolled between 6 aug 2011 and 17 Jan 2013.
    • 29 Apr 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top